In clinical settings, based on AR expression status in the thyroid tumor, a pro-senescence approach could be taken in combination with traditional treatments of radioiodine ablation, TSH suppression, thyroid hormone replacement therapy, and BRAF inhibitors, in order to reduce tumor mass before lobectomy or thyroidectomy. The gene discussed is BRAF; the disease is neoplasm.